These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1133 related articles for article (PubMed ID: 26187207)

  • 1. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of F-18 FDG PET/CECT vs. CECT for detecting recurrence of periampullary carcinoma and its prognostic significance.
    Santhosh S; Mittal BR; Kang M; Kapoor R; Gupta R; Rana S; Bhattacharya A; Bhasin D
    Abdom Imaging; 2015 Jun; 40(5):1131-7. PubMed ID: 25655637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
    Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
    Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary.
    Fencl P; Belohlavek O; Skopalova M; Jaruskova M; Kantorova I; Simonova K
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1783-92. PubMed ID: 17541584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
    Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
    Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
    Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
    Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
    Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
    Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
    Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of 18F-FDG PET/CT in patients with liver metastases.
    Chua SC; Groves AM; Kayani I; Menezes L; Gacinovic S; Du Y; Bomanji JB; Ell PJ
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1906-14. PubMed ID: 17713766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.